VERAXA Biotech (NASDAQ: VRXA) has reached a significant milestone in its oncology pipeline with the advancement of its VXA-222 bispecific antibody-drug conjugate (bsADC) program into the next stage of development. The company announced that the discovery phase of its collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz), has been successfully completed. With this milestone, VERAXA will now focus on engineering the final bispecific ADC candidate by leveraging its proprietary antibody engineering, linker, and conjugation technologies, and will proceed with preclinical validation.
The VXA-222 program, while not based on VERAXA's BiTAC platform, represents one of the company's more advanced development programs. It utilizes the company's proprietary technologies to combine the antibody binders identified through the OmniAb collaboration into a therapeutic candidate. This progress underscores VERAXA's commitment to building a diversified oncology pipeline that includes bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.
In addition to the development milestone, VERAXA has recently expanded its intellectual property portfolio with its first BiTAC-related patent filings, along with additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted, owned, or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047. This expansion of its IP estate is crucial for protecting its innovative technologies and maintaining a competitive edge in the biopharmaceutical industry.
The advancement of VXA-222 and the strengthening of its patent portfolio are important steps for VERAXA as it continues to develop novel cancer therapies. The company's progress reflects its strategic focus on leveraging its proprietary platforms to address significant unmet medical needs in oncology. With a robust pipeline and a solid intellectual property foundation, VERAXA is well-positioned to advance its candidates through preclinical and clinical development, potentially bringing new treatment options to patients with difficult-to-treat cancers.
For more information about VERAXA and its latest updates, visit the company's newsroom at https://ibn.fm/VRXA. Investors and stakeholders are encouraged to review the company's filings with the SEC for a comprehensive understanding of the risks and opportunities associated with its forward-looking statements.
